Medical treatments with Mesenchymal Stem Cells (MSCs)
Mesenchymal Stem Cells (MSCs) are one of the most famous stem cell type used in medicine. They have been shown to be effective for a wide range of diseases with a minimal risk profile. At the same time several hundred clinical studies are ongoing to investigate their regenerative abilities in greater detail. From a biological point-of-view, they are progenitor cells of connective tissues. This means that they are important for building and maintaining the healthy status of connective tissues throughout the whole body, and are known as stromal stem cells.
Likewise, they possess the ability to differentiate into a spectrum of other cell types, including chondrocytes (cartilage cells), osteoblasts (bone cells), adipocytes (fat cells), etc. This property classifies them as “multipotent stem cells” (being able to transform into many cell types).
There are several reasons of why they are the leading stem cell type in medical applications and clinical trials on humans:
- They are relatively easy to harvest and be isolated from:
- Fat tissue, known as adMSCs (adipose derived MSCs)
- Bone Marrow, known as bmMSCs (bone marrow MSCs)
- Umbilical Cord, known as ucMSC (umbilical cord MSCs)
- MSCs are relatively stable to culture and expand in the laboratory
- They can go through relatively many division cycles without losing their expression profile, health and division potential
- Numerous animal, clinical and scientific data collected for various disease models, including neurodegenerative diseases
- They possess little to no potential to grow into cancer cells
- As recent research revealed, their stem cell secretome profile is extraordinarily beneficial because it displays a wide range of regenerative and protective abilities to the body
- As such, MSCs are our favorite source for making our Stem Cell Secretome therapies.
Confocal microscopy image of Mesenchymal Stem Cells (MSCs) with florescence staining
All this knowledge lead scientists all over the world to invent a new generation of Stem Cell treatments: The Stem Cell Secretome. The secretome is designed for efficacy, safety and producing a high concentration of active components, e.g. growth factors and cytokines, responsible for their regenerative powers. ANOVA is the first company in Europe to apply Stem Cell Secretome Therapy for patients from all over the world. For more information on secretome (stem cell-based) treatments, please feel free to contact us.
Why do Mesenchymal Stem Cells have so much healing potential?
The Figure illustrates the effects of MSCs in clinical use. The therapeutic potential of MSCs relies on several unique properties as 1) the capacity to differentiate into various cell lineage, 2) the ability to secrete paracrine factors initiating healing and regeneration in the surrounding cells, 3) the ability to reduce inflammation and regulate immune response, 4) the ability to migrate to the exact site of injury. Figure from .
1. Gu W, Zhang F, Xue Q, Ma Z, Lu P, Yu B. Transplantation of bone marrow mesenchymal stem cells reduces lesion volume and induces axonal regrowth of injured spinal cord. Neuropathology. 2010; 30: 205-217.
2. Wilkins A, Kemp K, Ginty M, Hares K, Mallam E, Scolding N. Human bone marrow-derived mesenchymal stem cells secrete brain-derived neurotrophic factor which promotes neuronal survival in vitro. Stem Cell Res. 2009; 3: 6370
3. Wei X, Yang X, Han ZP, Qu FF, Shao L, Shi YF. Mesenchymal stem cells: a new trend for cell therapy. Acta Pharmacol Sin. 2013; 34: 747-754.
4. Wang S, Qu X, Zhao RC. Clinical applications of mesenchymal stem cells. J Hematol Oncol. 2014; 5: 19.
5. Farini, Andrea, et al. "Clinical applications of mesenchymal stem cells in chronic diseases." Stem cells international 2014 (2014).
6. Volarevic, Vladislav, et al. "Concise review: therapeutic potential of mesenchymal stem cells for the treatment of acute liver failure and cirrhosis." Stem Cells 32.11 (2014): 2818-2823.
7. Ikebe, Chiho, and Ken Suzuki. "Mesenchymal stem cells for regenerative therapy: optimization of cell preparation protocols." BioMed research international 2014 (2014).
8. Sharma, Ratti Ram, et al. "Mesenchymal stem or stromal cells: a review of clinical applications and manufacturing practices." Transfusion 54.5 (2014): 1418-1437.
9. Jo, Chris Hyunchul, et al. "Intra‐articular injection of mesenchymal stem cells for the treatment of osteoarthritis of the knee: a proof‐of‐concept clinical trial." Stem cells 32.5 (2014): 1254-1266.
10. Squillaro, Tiziana, Gianfranco Peluso, and Umberto Galderisi. "Clinical trials with mesenchymal stem cells: an update." Cell transplantation 25.5 (2016): 829-848.
11. Orozco, Lluis, et al. "Treatment of knee osteoarthritis with autologous mesenchymal stem cells: two-year follow-up results." Transplantation 97.11 (2014): e66-e68.
12. Filardo, Giuseppe, et al. "Mesenchymal stem cells for the treatment of cartilage lesions: from preclinical findings to clinical application in orthopaedics." Knee surgery, sports traumatology, arthroscopy 21.8 (2013): 1717-1729.
13. Jo, Chris Hyunchul, et al. "Intra‐articular injection of mesenchymal stem cells for the treatment of osteoarthritis of the knee: a proof‐of‐concept clinical trial." Stem cells 32.5 (2014): 1254-1266.
14. Vangsness, C. Thomas, et al. "Adult human mesenchymal stem cells delivered via intra-articular injection to the knee following partial medial meniscectomy." J Bone Joint Surg Am 96.2 (2014): 90-98.